Authorized purpose: BioticsAI assists healthcare professionals during and after fetal ultrasound acquisition and interpretation by detecting views and anatomical structures and facilitating quality-criteria verification on DICOM images and frames; it is a concurrent reading aid for the labeled GE ultrasound and prenatal population.
Clinical role
Concurrent reading and image-processing support during and after fetal anatomy examination
Images and patients
Ultrasound · Obstetric/Fetal
Key limitation
Keep in mind: Validated only with GE ultrasound; not intended for maternal ages outside 18-44 or gestation below 18 weeks, with validation covering 18-39 weeks. Quality assessment concerns expected structure presence. An unrecognized structure requires clinical review and does not itself establish a fetal anomaly.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: BioticsAI assists healthcare professionals during and after fetal ultrasound acquisition and interpretation by detecting views and anatomical structures and facilitating quality-criteria verification on DICOM images and frames; it is a concurrent reading aid for the labeled GE ultrasound and prenatal population.
Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Obstetric/Fetal Input: Still fetal ultrasound DICOM instances or individual frames from multiframe instances from GE ultrasound devices; images are submitted during or after the examination.
Who uses it?Intended users: Healthcare professionals including sonographers, OB/GYNs, maternal-fetal medicine specialists and fetal surgeons
What does the software produce?Output: AI-1 high-level anatomy labels, AI-2 per-class top-1 fetal plane labels, and AI-3 anatomical structure labels. Green/red/yellow indicators distinguish detected, not-detected and manual-verification items; DICOM viewing and report templates support DICOM SR export.
What is its most important limitation?Key limitation: Validated only with GE ultrasound; not intended for maternal ages outside 18-44 or gestation below 18 weeks, with validation covering 18-39 weeks. Quality assessment concerns expected structure presence. An unrecognized structure requires clinical review and does not itself establish a fetal anomaly.
Clinical takeaway. Clinical role: BioticsAI assists healthcare professionals during and after fetal ultrasound acquisition and interpretation by detecting views and anatomical structures and facilitating quality-criteria verification on DICOM images and frames; it is a concurrent reading aid for the labeled GE ultrasound and prenatal population.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports standalone performance testing on 11,186 fetal ultrasound images from 296 patients at a single US site, independent of model development data. Across all image qualities, detection of 5 high-level fetal anatomy sections had sensitivity 0.934 (95% CI 0.929, 0.94) and specificity 0.989 (0.988, 0.99); per-class top-1 detection of 13 fetal planes had sensitivity 0.960 (0.955, 0.964) and specificity 0.997 (0.997, 0.998). Fetal anatomical structure classification results are also reported. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
BioticsAI assists healthcare professionals during and after fetal ultrasound acquisition and interpretation by detecting views and anatomical structures and facilitating quality-criteria verification on DICOM images and frames; it is a concurrent reading aid for the labeled GE ultrasound and prenatal population.
Still fetal ultrasound DICOM instances or individual frames from multiframe instances from GE ultrasound devices; images are submitted during or after the examination.
Validated only with GE ultrasound; not intended for maternal ages outside 18-44 or gestation below 18 weeks, with validation covering 18-39 weeks. Quality assessment concerns expected structure presence. An unrecognized structure requires clinical review and does not itself establish a fetal anomaly.
Exact FDA submission
Checked 2026-09-05
The comparison table says Real Time: No, despite real-time wording elsewhere in the description; no streaming or latency guarantee is assigned.
The exact FDA document reports standalone performance testing on 11,186 fetal ultrasound images from 296 patients at a single US site, independent of model development data. Across all image qualities, detection of 5 high-level fetal anatomy sections had sensitivity 0.934 (95% CI 0.929, 0.94) and specificity 0.989 (0.988, 0.99); per-class top-1 detection of 13 fetal planes had sensitivity 0.960 (0.955, 0.964) and specificity 0.997 (0.997, 0.998). Fetal anatomical structure classification results are also reported. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "BioticsAI conducted a standalone performance testing on a dataset of 11,186 fetal ultrasound images in the United States across 296 patients" … "population from a single site (across multiple ultrasound screening units and machine instances) in the United States. This dataset was independent of the data used during model development". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports standalone performance testing on 11,186 fetal ultrasound images from 296 patients at a single US site, independent of model development data. Across all image qualities, detection of 5 high-level fetal anatomy sections had sensitivity 0.934 (95% CI 0.929, 0.94) and specificity 0.989 (0.988, 0.99); per-class top-1 detection of 13 fetal planes had sensitivity 0.960 (0.955, 0.964) and specificity 0.997 (0.997, 0.998). Fetal anatomical structure classification results are also reported. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "BioticsAI conducted a standalone performance testing on a dataset of 11,186 fetal ultrasound images in the United States across 296 patients" … "population from a single site (across multiple ultrasound screening units and machine instances) in the United States. This dataset was independent of the data used during model development". Read from the exact FDA decision document on 2026-11-14.
DesignManufacturer held-out standalone testing across anatomy, plane and anatomical-structure classification tasks
Population11,186 images from 296 patients at one US site, including variation in BMI, ethnicity, gestational age, twins and abnormalities
Scopeexact submission
Tested versionBioticsAI configuration in K250959
Samplen=296
Sites1
IndependenceSponsor or vendor study
K250959
Multiple imaging units at a single site. Dataset excluded development/operating-point selection data. Reference-annotation details remain incompletely abstracted; no prospective patient-outcome claim is made.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Still fetal ultrasound DICOM instances or individual frames from multiframe instances from GE ultrasound devices; images are submitted during or after the examination.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Client-provided DIMSE connectivity exports ultrasound DICOM to the BioticsAI DICOM Adapter; populated reports can be exported to the clinic PACS as DICOM SR over DIMSE.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: AI-1 high-level anatomy labels, AI-2 per-class top-1 fetal plane labels, and AI-3 anatomical structure labels. Green/red/yellow indicators distinguish detected, not-detected and manual-verification items; DICOM viewing and report templates support DICOM SR export.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Client-provided DIMSE connectivity exports ultrasound DICOM to the BioticsAI DICOM Adapter; populated reports can be exported to the clinic PACS as DICOM SR over DIMSE.
BioticsAI's official site describes fetal-screening completeness/quality assessment and report generation, and provides a demonstration request route.
product family · checked 2026-09-05
Broader marketing statements about identifying fetal anomalies and real-time feedback are not treated as exact K250959 indications or validated outcomes.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-05Last searched
23Fields reviewed
11Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
Stored prospective fetal-anatomy classification title/date screened. Live page established citation DOI 10.1002/ijgo.70779, but subsequent abstract retrieval was blank. Exact tested device/version and methods remain unresolved; no study or metric promoted. Stored trial array empty. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, literature index, trial registry, stored candidate metadata, stored recall candidates, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-05 - Exact FDA submission
The official site offers demo/sales contact but no verified price, unit, minimum volume or implementation/support fee for K250959.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "Bioticsai reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. No result was a vendor or payer page naming this product with coding or payment; any results were general billing guidance. This records what was found, not that none exists.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-05 - Exact FDA submission
Regulatory cybersecurity testing and cloud descriptions do not establish a current scoped attestation, retention policy, region or installed access controls.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-05 - Exact FDA submission
Exact onboarding, competency, handling of unsupported views and support commitments require current vendor documentation.
Monitoring: Not verified - checked 2026-09-05 - Exact FDA submission
Editorial acceptance questions: verify missing-view/manual-review handling, maternal/gestational eligibility and DICOM SR export against local protocols; no supplied monitoring service is verified.
Authorized purpose: Automatic standard-view detection and frame extraction to support acquisition and interpretation of second- or third-trimester fetal heart ultrasound.
Authorized purpose: Concurrent physician reading aid for specified abnormal fetal ultrasound findings; patient management must not rely solely on the analysis.
Authorized purpose: Butterfly Gestational Age Tool estimates gestational age for a singleton intrauterine pregnancy presumed to be 16 to 37 weeks within the labeled Butterfly ultrasound workflow; qualified professionals must review the output.
Authorized purpose: Concurrent or post-exam fetal ultrasound aid that identifies and characterizes eight abnormal findings for interpreting-physician review; not the sole basis for management.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.